Ifp Advisors, Inc Krystal Biotech, Inc. Transaction History

Ifp Advisors, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jul 30, 2024	BUY	$108.01 - $179.35 $756 - $1,255	7 Added 2.69%	267 $47,000
Q4 2023 Jan 09, 2024	BUY	$96.0 - $128.29 $21,984 - $29,378	229 Added 738.71%	260 $32,000
Q3 2023 Oct 12, 2023	BUY	$108.51 - $130.22 $3,363 - $4,036	31 New	31 $3,000
Q3 2021 Oct 06, 2021	SELL	$52.01 - $71.77 $0 - $0	0 Closed	0 $0
Q2 2021 Jul 13, 2021	BUY	$62.14 - $81.82 $0 - $0	0 New	0 $0
Q1 2021 Apr 30, 2021	BUY	$59.42 - $85.46 $0 - $0	0 New	0 $0
Q4 2020 Jan 25, 2021	BUY	$40.64 - $61.38 $0 - $0	0 New	0 $0
Q3 2020 Oct 29, 2020	BUY	$37.76 - $48.49 $0 - $0	0 New	0 $0

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.89B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.